New Cardiovascular Biomarkers in Breast Cancer Patients Undergoing Doxorubicin-Based Chemotherapy.

Rodrigo Mendonça Cardoso PestanaJúnea Paolucci Paiva SilvinoAngélica Navarro de OliveiraCintia Esteves SoaresAdriano de Paula SabinoRicardo SimõesKarina Braga Gomes

Published in: Arquivos brasileiros de cardiologia (2024)

GDF15 is an emerging biomarker with potential clinical applicability in this scenario. FABPs are proteins related to adiposity, which are potentially involved in breast cancer biology. sCD14 and ucMGP engage in inflammatory and vascular calcification. The evaluation of these novel cardiovascular biomarkers could be useful in the management of breast cancer chemotherapy with DOXO.

Keyphrases

locally advanced
drug delivery
oxidative stress
chronic kidney disease
insulin resistance
squamous cell carcinoma
cancer therapy
human health
young adults
risk assessment
metabolic syndrome
climate change
skeletal muscle
drug induced